Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
190 questions in 24 reviews · Epilepsy
current versionsNo studies 190 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Lamotrigine plus ASMs vs placebo plus ASMs Number of participants free from all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Lamotrigine plus ASMs vs placebo plus ASMs Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs vs placebo plus ASMs Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Rufinamide plus ASMs vs placebo plus ASMs Number of participants free from all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Rufinamide plus ASMs vs placebo plus ASMs Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Rufinamide plus ASMs vs other ASM plus ASMs Number of participants free from all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Rufinamide plus ASMs vs other ASM plus ASMs Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Rufinamide plus ASMs vs other ASM plus ASMs Number of participants with ≥ 50% reduction in all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs vs placebo plus ASMs Number of participants with ≥ 50% reduction in all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Topiramate plus ASMs vs placebo plus ASMs Number of participants free from all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Topiramate plus ASMs vs placebo plus ASMs Number of participants with ≥ 50% reduction in all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Cinromide plus ASMs vs placebo plus ASMs Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age1 Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Clobazam (low, medium and high doses) plus ASMs vs placebo plus ASMs Number of participants free from all seizures · Lennox‐Gastaut syndrome, any age Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Topiramate vs placebo Number of participants who were seizure‐free · people with juvenile myoclonic epilepsy Topiramate for juvenile myoclonic epilepsy (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (50 mg/kg or 100 mg/kg) vs dexmedetomidine oral (2 µg/kg or 3 µg/kg) Proportion of children who successfully completed neurodiagnostic procedure without interruption by the child awakening · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (100 mg/kg or 75 mg/kg) vs midazolam (intranasal 0.2 mg/kg or oral 0.5 mg/kg) Proportion of children who successfully completed neurodiagnostic procedure without interruption by the child awakening · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (100 mg/kg or 75 mg/kg) vs midazolam (intranasal 0.2 mg/kg or oral 0.5 mg/kg) Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (50 mg/kg or 100 mg/kg) vs dexmedetomidine oral (2 µg/kg or 3 µg/kg) Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (50 mg/kg) vs melatonin oral Proportion of children who successfully completed neurodiagnostic procedure without interruption by the child awakening · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (50 mg/kg) vs melatonin oral Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (50 mg/kg) vs melatonin oral Time to adequate sedation (minutes or as measured by specific validated scales such as the Ramsay Sedation Score) · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (50 mg/kg) vs melatonin oral Proportion of children who had sedation failure or inadequate level of sedation · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (50 mg/kg + 50 mg/kg) vs hydroxyzine hydrochloride oral (1 mg/kg + 1 mg/kg) Proportion of children who successfully completed neurodiagnostic procedure without interruption by the child awakening · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (50 mg/kg + 50 mg/kg) vs hydroxyzine hydrochloride oral (1 mg/kg + 1 mg/kg) Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (70 mg/kg) vs promethazine oral (1 mg/kg) Proportion of children who successfully completed neurodiagnostic procedure without interruption by the child awakening · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (70 mg/kg) vs promethazine oral (1 mg/kg) Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (60 mg/kg) vs music therapy Proportion of children who successfully completed neurodiagnostic procedure without interruption by the child awakening · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (60 mg/kg) vs music therapy Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (60 mg/kg) vs music therapy Number of children with clinical adverse events (any) · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (75 mg/kg) vs pentobarbital intravenous (5 mg/kg) Proportion of children who successfully completed neurodiagnostic procedure without interruption by the child awakening · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Chloral hydrate oral (75 mg/kg) vs pentobarbital intravenous (5 mg/kg) Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures Chloral hydrate as a sedating agent for neurodiagnostic procedures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Levetiracetam vs phenobarbital Proportion with seizure freedom in dominantly inherited AD · patients with AD and epileptic seizures Treatment of epilepsy for people with Alzheimer's disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Levetiracetam vs phenobarbital Improvement in quality of life · patients with AD and epileptic seizures Treatment of epilepsy for people with Alzheimer's disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Lamotrigine vs phenobarbital Proportion with seizure freedom in dominantly inherited AD · patients with AD and epileptic seizures Treatment of epilepsy for people with Alzheimer's disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Lamotrigine vs phenobarbital Improvement in quality of life · patients with AD and epileptic seizures Treatment of epilepsy for people with Alzheimer's disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Levetiracetam vs lamotrigine Proportion with seizure freedom in dominantly inherited AD · people with AD and epileptic seizures Treatment of epilepsy for people with Alzheimer's disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Levetiracetam vs lamotrigine Improvement in quality of life · people with AD and epileptic seizures Treatment of epilepsy for people with Alzheimer's disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Norethisterone vs placebo Seizure freedom · women with seizures due to catamenial epilepsy Treatments for seizures in catamenial (menstrual‐related) epilepsy (2021) · Cochrane | no estimate extracted | NR | No studies |
Progesterone vs placebo Quality of life · women with seizures due to catamenial epilepsy Treatments for seizures in catamenial (menstrual‐related) epilepsy (2021) · Cochrane | no estimate extracted | NR | No studies |
Norethisterone vs placebo Responder rate · women with seizures due to catamenial epilepsy Treatments for seizures in catamenial (menstrual‐related) epilepsy (2021) · Cochrane | no estimate extracted | NR | No studies |
Norethisterone vs placebo Quality of life · women with seizures due to catamenial epilepsy Treatments for seizures in catamenial (menstrual‐related) epilepsy (2021) · Cochrane | no estimate extracted | NR | No studies |
Ketogenic diet (KD) vs usual care Cognition and behaviour · adults (aged 16 years and over) with drug‐resistant epilepsy Ketogenic diets for drug‐resistant epilepsy (2020) · Cochrane | no estimate extracted | NR | No studies |
Ketogenic diet (KD) vs usual care Quality of life · adults (aged 16 years and over) with drug‐resistant epilepsy Ketogenic diets for drug‐resistant epilepsy (2020) · Cochrane | no estimate extracted | NR | No studies |
Ketogenic diets (KDs) vs other KDs Cognition and behaviour · children (aged 4 months to 16 years) with drug‐resistant epilepsy Ketogenic diets for drug‐resistant epilepsy (2020) · Cochrane | no estimate extracted | NR | No studies |
Ketogenic diets (KDs) vs other KDs Quality of life · children (aged 4 months to 16 years) with drug‐resistant epilepsy Ketogenic diets for drug‐resistant epilepsy (2020) · Cochrane | no estimate extracted | NR | No studies |
Ketogenic diets (KDs) vs other KDs Cognition and behaviour · adults (aged 18 years and over) with drug‐resistant epilepsy Ketogenic diets for drug‐resistant epilepsy (2020) · Cochrane | no estimate extracted | NR | No studies |
Ketogenic diets (KDs) vs other KDs Quality of life · adults (aged 18 years and over) with drug‐resistant epilepsy Ketogenic diets for drug‐resistant epilepsy (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Functional outcome (number of people with disabilities) · people with postcraniotomy seizures Antiepileptic drugs as prophylaxis for postcraniotomy seizures (2020) · Cochrane | no estimate extracted | NR | No studies |
Interventions for vs no intervention Number of other deaths (unrelated to SUDEP) · cases of SUDEP and matched controls (number of deaths due to SUDEP) and consecutive people with epilepsy from a… Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP) (2020) · Cochrane | no estimate extracted | NR | No studies |
Interventions for vs no intervention Number of hospital attendances for seizures · cases of SUDEP and matched controls (number of deaths due to SUDEP) and consecutive people with epilepsy from a… Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP) (2020) · Cochrane | no estimate extracted | NR | No studies |